당뇨망막병증 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Diabetic Retinopathy Market size is expected to reach USD 20.19 Billion in 2034 from USD 6.22 Billion (2025) growing at a CAGR of 13.97% during 2026-2034.

The global diabetic retinopathy market is expanding significantly due to the rising global burden of diabetes. As the number of diabetic patients increases, the risk of vision-related complications is also growing, driving demand for effective diagnostic and treatment solutions. Early screening programs and improved imaging technologies have enhanced detection rates, supporting market growth.

Major drivers include advancements in anti-VEGF therapies, laser treatments, and surgical interventions. Increasing awareness about regular eye examinations and government initiatives promoting diabetes management are further strengthening market expansion. The integration of artificial intelligence in retinal imaging is also improving diagnostic accuracy and efficiency.

Looking forward, the market is expected to benefit from continued innovation in biologic therapies and long-acting treatment options. Teleophthalmology services and digital health platforms may expand access to eye care, particularly in rural areas. As healthcare systems focus on preventing diabetes-related complications, the demand for diabetic retinopathy treatments is projected to grow steadily in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Proliferative Diabetic Retinopathy
• Diabetic Macular Edema (DME)

By Treatment Type

• Anti VEGF Drug
• Steroid Implants
• Laser Surgeries
• Vitrectomy

COMPANIES PROFILED

• Alimera Science, AbbVie, Ampio Pharmaceuticals, Bayer, Kowa, Novartis, Pfizer, Regeneron Pharmaceuticals, FHoffmannLa Roche, Valeant Pharmaceuticals Bausch Health Companies
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETIC RETINOPATHY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Proliferative Diabetic Retinopathy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Diabetic Macular Edema (DME) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETIC RETINOPATHY MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Anti VEGF Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Steroid Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Laser Surgeries Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Vitrectomy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETIC RETINOPATHY MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By Treatment Type
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By Treatment Type
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By Treatment Type
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By Treatment Type
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By Treatment Type
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL DIABETIC RETINOPATHY INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Alimera Science
  • 8.2.2 AbbVie
  • 8.2.3 Ampio Pharmaceuticals
  • 8.2.4 Bayer
  • 8.2.5 Kowa
  • 8.2.6 Novartis
  • 8.2.7 Pfizer
  • 8.2.8 Regeneron Pharmaceuticals
  • 8.2.9 F-Hoffmann-La Roche
  • 8.2.10 Valeant Pharmaceuticals (Bausch Health Companies)